ReviewDermatology and therapy2020
Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review.
Review in Dermatology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Baricitinib and low-dose prednisone for very severe alopecia areata: A retrospective case series.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics.Frontiers in medicine · 2026Review
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement.The Australasian journal of dermatology · 2025Article
- Comparison of Current International Guidelines for the Management of Alopecia Areata-Comprehensive Review.International journal of molecular sciences · 2025Review
- Sexual Dysfunction in Alopecia Areata: A Systematic Review.Journal of clinical medicine · 2025Review
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.Cureus · 2025Review
- Survey on Alopecia Areata Patients' Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study.Annals of dermatology · 2024Article
- Korean Consensus Criteria for the Severity Classification of Alopecia Areata.Annals of dermatology · 2024Article
- Article
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment.Frontiers in pharmacology · 2024Article
- Review
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment.Annals of dermatology · 2023Article
- Alopecia Areata: An Updated Review for 2023.Journal of cutaneous medicine and surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCyclosporine is commonly used in treatment for alopecia areata. It can be administered as a monotherapy or in combination with systemic corticosteroids, with various outcomes.
methodsEfficacy of cyclosporine with and without systemic corticosteroids for alopecia areata was evaluated by a systematic review. Cochrane, EBSCOhost, Pubmed, Scopus and Web of Science databases were searched. Only studies published before January 2020 were included.
resultsA total of 2104 studies were initially examined, of which 14 were eligible for the systematic review. Among 340 reported cases, 213 had focal, multifocal or ophiasis form of alopecia areata, 60 were diagnosed with alopecia totalis and 67 with alopecia universalis. The mean response rate in the whole group of patients at the end of treatment was 65.00% (221/340; range 25-100%). Hair regrowth rate was higher in the group with cases of alopecia areata limited to scalp (124/165; mean 75.15%; range 40-100%) than in the cases with alopecia totalis (30/46; mean 65.22%; range 25-100%) or alopecia universalis (24/52; mean 46.15%; range 25-100%). The combined therapy with systemic corticosteroids was superior to the monotherapy (152/219; mean 69.41%; 0-80% vs. 69/121; mean 57.02%; range 6.67-100%) and had a lower recurrence rate (39/108; mean 36.11% vs. 34/46; mean 73.91%, respectively). The combined treatment with methylprednisolone was significantly more effective when compared to the cyclosporine monotherapy (124/183; mean 67.76%; range 0-80% vs. 69/121; mean 57.02%; range 6.67-100%). The mean time of treatment was 6.75 months (range 2-36). LIMITATIONS: Limitations of our study were the retrospective character of included studies, differences in doses of prescribed drugs, and duration of the treatment and follow-up times.
conclusionCyclosporine in combination with oral systemic corticosteroids is more effective than in monotherapy for severe alopecia areata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.